Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lucitanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 20/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 1.00 |
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 1.00 |
| ▸ | FGFR2 known ✓ | P21802 | 2/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 10/20 | 1.00 |
| ▸ | LYN | P07948 | 4/20 | 1.00 |
| ▸ | PDXK | O00764 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 1/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 1/20 | 1.00 |
| ▸ | DDR2 | Q16832 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 14/20 | 0.79 |
| ▸ | LCK | P06239 | 14/20 | 0.79 |
| ▸ | TEK | Q02763 | 14/20 | 0.79 |
| ▸ | MET | P08581 | 12/20 | 0.79 |
| ▸ | ABL1 | P00519 | 2/20 | 0.66 |
| ▸ | FGR | P09769 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lucitanib SCHEMBL29375046 | 1.00 | KDR (1.00) | KDRAURKBLYNFLT1FGFR1 | |
| Lucitanib SCHEMBL29363689 | 1.00 | KDR (1.00) | KDRAURKBLYNFLT1FGFR1 | |
| Lucitanib SCHEMBL29365836 | 1.00 | KDR (1.00) | KDRAURKBLYNFLT1FGFR1 | |
| Lucitanib SCHEMBL29379692 | 0.99 | KDR (1.00) | KDRAURKBLYNFLT1FGFR1 | |
| Lucitanib SCHEMBL26928177 | 0.99 | KDR (1.00) | KDRAURKBLYNFLT1FGFR1 | |
| Lucitanib SCHEMBL30737889 | 0.99 | KDR (1.00) | KDRAURKBLYNFLT1FGFR1 | |
| SCHEMBL2097763 | 0.91 | KDR (0.83) | KDRAURKBLYNFLT1FGFR1 | |
| SCHEMBL2101349 | 0.90 | KDR (0.81) | KDRAURKBLYNFLT1FGFR1 | |
| SCHEMBL381963 | 0.90 | KDR (0.81) | KDRAURKBLYNFLT1FGFR1 | |
| SCHEMBL2099219 | 0.90 | KDR (0.81) | KDRAURKBLYNFLT1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2786750-B2 | AGENT FOR REDUCING ADVERSE SIDE EFFECTS OF KINASE INHIBITOR | EA PHARMA CO LTD (JP) | 2023-06-28 | — | — | EP | claimed |
| CN-111454206-A | Process for producing antitumor agent and crystals thereof | 爱德程制药有限公司 | 2020-07-28 | — | — | CN | claimed |
| US-9783498-B2 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and its crystalline | Advenchen Pharmaceuticals, LLC (US) | 2017-10-10 | — | — | US | claimed |
| EP-2786750-B1 | AGENT FOR REDUCING ADVERSE SIDE EFFECTS OF KINASE INHIBITOR | AJINOMOTO KK (JP) | 2016-06-08 | — | — | EP | claimed |
| US-20150353496-A1 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and its crystalline | ADVENCHEN PHARMACEUTICALS LLC (US) | 2015-12-10 | — | — | US | claimed |
| EP-2945931-A1 | PROCESS FOR PREPARING THE ANTI-TUMOR AGENT 6-(7-((1-AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND ITS CRYSTALLINE | Advenchen Pharmaceuticals LLC (US) | 2015-11-25 | — | — | EP | claimed |
| US-9012645-B2 | Process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof | CLOVIS ONCOLOGY ITALY S.R.L. (IT) | 2015-04-21 | — | — | US | claimed |
| WO-2015019030-A1 | NOVEL COMBINATION OF 6-({7-[(1-AMINOCYCLOPROPYL)METHOXY]-6-METHOXYQUINOLIN-4-YL}OXY)-N-METHYLNAPHTHALENE-1-CARBOXAMIDE AND AN ANTI-OESTROGEN IN BREAST CANCER | LES LABORATOIRES SERVIER (FR) | 2015-02-12 | — | — | WO | claimed |
| EP-2786750-A1 | AGENT FOR REDUCING ADVERSE SIDE EFFECTS OF KINASE INHIBITOR | Ajinomoto Co., Inc. (JP) | 2014-10-08 | — | — | EP | claimed |
| US-20140275183-A1 | AGENT FOR REDUCING SIDE EFFECTS OF KINASE INHIBITOR | AJINOMOTO CO., INC. (JP) | 2014-09-18 | — | — | US | claimed |
| EP-2408739-B1 | A PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE SPA IN ABBREVIATED FORM EOS SPA (IT) | 2013-08-14 | — | — | EP | claimed |
| WO-2013081154-A1 | AGENT FOR REDUCING ADVERSE SIDE EFFECTS OF KINASE INHIBITOR | 味の素株式会社 (JP) | 2013-06-06 | — | — | WO | claimed |
| EP-2125777-B1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LAB LLC (US) | 2013-04-10 | — | — | EP | claimed |
| US-8163923-B2 | Benzyl 1-((6-methoxy-4-(5-(methylcarbamoyl)naphthalen-2-yloxy)quinolin-7-yloxy)methyl)cyclo-propylcarbamate; cancers associated with protein tyrosine kinases | ADVENCHEN LABORATORIES, LLC (US) | 2012-04-24 | — | — | US | claimed |
| EP-2408739-A1 | A PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | EOS Ethical Oncology Science S.p.A. In Abbreviated From EOS S.p.A. (IT) | 2012-01-25 | — | — | EP | claimed |
| US-20120010415-A1 | PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | CLOVIS ONCOLOGY ITALY S.R.L. (IT) | 2012-01-12 | — | — | US | claimed |
| WO-2010105761-A1 | A PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE S.P.A. IN ABBREVIATED FORM EOS S.P.A. (IT) | 2010-09-23 | — | — | WO | claimed |
| EP-2125777-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | Advenchen Laboratories, LLC (US) | 2009-12-02 | — | — | EP | claimed |
| US-20080227812-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | ADVENCHEN LABORATORIES, LLC | 2008-09-18 | — | — | US | claimed |
| WO-2008112408-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2008-09-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353496-A1 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and its crystalline | CCNA1, CDK10, CCNT1 | KDR 4586/4885FLT1 2457/4885FGFR1 3051/4885 |
| US-20080227812-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | TEK, KDR, TIE1 | KDR 2/4885FLT1 4/4885FGFR1 22/4885 |
| US-20120010415-A1 | PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | CYP2B6, CYP2A6, NAT1 | KDR 4677/4885FLT1 4277/4885FGFR1 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.